McElhaugh Michael J.'s Form 4 filing
Arbutus Biopharma Corp (ABUS) · filed Feb 5, 2024
- Accession no.
- 0001447028-24-000025
- Filed
- Feb 5, 2024
- Trade date
- Feb 1-2, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $23.5K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| McElhaugh Michael J.CIK 0001635326 | Director, Officer (Interim President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 1, 2024 | Common Shares | AGrant or awardAcquired | +123,800 | $0.00 | $0 | 1,514,957 | Direct | |
| Feb 2, 2024 | Common Shares | SSaleDisposed | −10,164 | $2.31 | −$23,478.84 | 1,504,793 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 1, 2024 | Common Shares | AGrant or awardAcquired | +495,100 | $0.00 | $0 | 495,100 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.